Univariate outcome probabilities by donor type and disease state
| . | 0-1 HLA-antigen mismatched related or HLA-matched unrelated donor . | 2,3-HLA antigen mismatched related or HLA-mismatched unrelated donor . | ||||
|---|---|---|---|---|---|---|
| NonT-depleted . | Narrow Sp antibody . | Other T-depletion technique . | NonT-depleted . | Narrow Sp antibody . | Other T-depletion technique . | |
| Graft failure (5 y) | 7 ± 2% | 5 ± 3% | 22 ± 6% | 7 ± 4% | 16 ± 6% | 28 ± 8% |
| Grades 2-4 acute GVHD (100 d) | 54 ± 4% | 35 ± 7% | 35 ± 6% | 61 ± 8% | 50 ± 7% | 37 ± 9% |
| Chronic GVHD (5 y) | 57 ± 8% | 54 ± 9% | 47 ± 11% | 54 ± 13% | 68 ± 11% | 37 ± 16% |
| TRM (5 y) | 51 ± 4% | 58 ± 8% | 62 ± 7% | 57 ± 10% | 68 ± 8% | 88 ± 9% |
| Relapse (5 y) | ||||||
| 1st CR or 1st CP | 17 ± 6% | 23 ± 14% | 40 ± 15% | 32 ± 20% | 18 ± 16% | 42 ± 38% |
| ≥ 2nd CR or AP | 32 ± 9% | 17 ± 12% | 60 ± 24% | 27 ± 16% | 21 ± 13% | 46 ± 28% |
| Relapse or BP | 74 ± 12% | 74 ± 17% | 49 ± 22% | 47 ± 22% | 35 ± 15% | 67 ± 28% |
| LFS (5 y) | ||||||
| 1st CR or 1st CP | 43 ± 6% | 40 ± 12% | 25 ± 8% | 39 ± 15% | 42 ± 16% | 17 ± 15% |
| ≥2nd CR or AP | 33 ± 7% | 33 ± 11% | 12 ± 9% | 32 ± 13% | 22 ± 10% | 4 ± 7% |
| Relapse or BP | 13 ± 7% | 8 ± 7% | 16 ± 12% | 10 ± 15% | 15 ± 10% | 2 ± 4% |
| . | 0-1 HLA-antigen mismatched related or HLA-matched unrelated donor . | 2,3-HLA antigen mismatched related or HLA-mismatched unrelated donor . | ||||
|---|---|---|---|---|---|---|
| NonT-depleted . | Narrow Sp antibody . | Other T-depletion technique . | NonT-depleted . | Narrow Sp antibody . | Other T-depletion technique . | |
| Graft failure (5 y) | 7 ± 2% | 5 ± 3% | 22 ± 6% | 7 ± 4% | 16 ± 6% | 28 ± 8% |
| Grades 2-4 acute GVHD (100 d) | 54 ± 4% | 35 ± 7% | 35 ± 6% | 61 ± 8% | 50 ± 7% | 37 ± 9% |
| Chronic GVHD (5 y) | 57 ± 8% | 54 ± 9% | 47 ± 11% | 54 ± 13% | 68 ± 11% | 37 ± 16% |
| TRM (5 y) | 51 ± 4% | 58 ± 8% | 62 ± 7% | 57 ± 10% | 68 ± 8% | 88 ± 9% |
| Relapse (5 y) | ||||||
| 1st CR or 1st CP | 17 ± 6% | 23 ± 14% | 40 ± 15% | 32 ± 20% | 18 ± 16% | 42 ± 38% |
| ≥ 2nd CR or AP | 32 ± 9% | 17 ± 12% | 60 ± 24% | 27 ± 16% | 21 ± 13% | 46 ± 28% |
| Relapse or BP | 74 ± 12% | 74 ± 17% | 49 ± 22% | 47 ± 22% | 35 ± 15% | 67 ± 28% |
| LFS (5 y) | ||||||
| 1st CR or 1st CP | 43 ± 6% | 40 ± 12% | 25 ± 8% | 39 ± 15% | 42 ± 16% | 17 ± 15% |
| ≥2nd CR or AP | 33 ± 7% | 33 ± 11% | 12 ± 9% | 32 ± 13% | 22 ± 10% | 4 ± 7% |
| Relapse or BP | 13 ± 7% | 8 ± 7% | 16 ± 12% | 10 ± 15% | 15 ± 10% | 2 ± 4% |
sp, specificity; GVHD, graft-versus-host disease; TRM, transplant-related mortality; CR, complete remission; CP, chronic phase; AP, accelerated phase; BP, blast phase; LFS, leukemia-free survival.